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http://www.biomedcentral.com/1471-2474/15/237STUDY PROTOCOL Open AccessThe effect of triclosan coated sutures on rate of
Surgical Site Infection after hip and knee
replacement: a protocol for a double-blind
randomised controlled trial
Andrew P Sprowson1*, Cyrus D Jensen2, Nick Parsons1, Paul Partington2, Kevin Emmerson2, Ian Carluke2,
Seif Asaad2, Roland Pratt2, Scott Muller2 and Mike R Reed2Abstract
Background: 187,000 hip and knee joint replacements are performed every year in the National Health Service
(NHS). One of the commonest complications is surgical site infection (SSI), and this represents a significant burden
in terms of patient morbidity, mortality and cost to health services around the world. The aim of this randomised
controlled trial (RCT) is to determine if the addition of triclosan coated sutures to a standard regimen can reduce
the rate of SSI after total knee replacement (TKR) and total hip replacement (THR).
Methods: 2400 patients due to undergo a total hip or knee replacement are being recruited into this two-centre
RCT. Participants are recruited before surgery and randomised to either standard care or intervention group.
Participants, outcome assessors and statistician are blind to treatment allocation throughout the study. The
intervention consists of triclosan coated sutures vs. standard non-coated sutures. The primary outcome is the Health
protection Agency (HPA) defined superficial surgical site infection at 30 days. Secondary outcomes include HPA
defined deep surgical site infection at 12 months, length of hospital stay, critical care stay, and payer costs.
Discussion: To date there are no orthopaedic randomised controlled trials on this scale assessing the effectiveness of
a surgical intervention, particularly those that can be translated across the surgical specialities. The results from this trial
will inform evidence-based recommendations for suture selection in the management of patients undergoing total hip
or knee replacement. If triclosan coated sutures are found to be an effective intervention, implementation into clinical
practice could improve long-term outcomes for patients undergoing hip and knee replacement.
Trial registration: Current Controlled Trials ISRCTN 17807356.Background
Total hip replacements (THR) and total knee replacements
(TKR) are performed for relief of debilitating pain second-
ary to arthritis, and are the commonest forms of joint re-
placement performed in the UK. Over 187,000 hip and
knee replacements were performed in 2012 [1] in England
and Wales. Over the past decade there has been a stark rise
in the number performed due to; earlier diagnosis, im-
proved availability to healthcare resources, awareness
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unless otherwise stated.2030, the demand for primary total hip replacement is esti-
mated to grow by 174% and the demand for primary total
knee replacement is projected to grow by 673% [2] in the
United States.
TKR and THR are safe, with relatively low risk of compli-
cations. However, Surgical site infection (SSI) is potentially
a very serious complication, which currently occurs in
around 1 out of every 100 joint replacements performed
[3]. A multitude of risk factors influence the development
of SSIs and awareness of these will help to promote effect-
ive preventive strategies [4,5]. A surgical site is the incision
made in skin by a surgeon to carry out a surgical proced-
ure, and an infection occurs when microorganisms get intoral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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defined as affecting the superficial or deeper tissues han-
dled during the procedure [6]. This complication repre-
sents an enormous personal cost to the patient and a very
significant cost to the NHS - in the region of £61 million
each year [7].
The aim of closure of a surgical wound is to promote
rapid healing by opposition of skin edges to leave a cos-
metically acceptable scar [8]. The technique should be
watertight, tension free, and should be without inverting
the skin edges. Delayed wound healing especially in high
risk groups, such as elderly, diabetic, immunocomprom-
ised patients can delay recovery and progress to deep
wound infection. This increases morbidity, mortality,
and has huge cost implications.
A commonly used absorbable braided synthetic fibre
suture (Vicryl) is used ubiquitously across surgical spe-
cialities, coated with equal parts of a copolymer of lac-
tide and glactide. This mixture forms an absorbable,
adherent, non-flaking lubricant. As a plain suture, it ex-
hibits tissue drag and “chatter” as it is tied. The suture
elicits only a mild tissue reaction and was one of the
first synthetic absorbable sutures developed for applica-
tions for which chromic gut could not be used. It is
absorbed predictably as it retains 65% of its strength at
14 days after implantation, 40% at 21 days and absorp-
tion is complete by 70 days [9].
To enhance the antimicrobial characteristic of a su-
ture, triclosan has been added (Vicryl plus), which al-
though not an antibiotic, acts as a broad-spectrum
antibacterial agent. Triclosan has been effectively used
in consumer products for more than 30 years [10]. In
vitro studies demonstrate that triclosan coated sutures
create an “active zone” around the suture, inhibiting
staphylococcus aureus, staphylococcus epidermidis and
methicillin resistant strains of staphylococcus (MRSA
and MRSE), the leading surgical site bacteria, from col-
onizing on the suture for a minimum of 48 hours
[11-14].
The aim of this trial is to determine if using a triclosan
coated suture can significantly reduce the rate of superfi-
cial SSI at 30 days after primary TKR and THR.Methods
The Northumbria Arthroplasty Suture Study (NASS) is an
on-going two-centre double blind randomised controlled
trial conducted at Northumbria NHS Foundation Trust,
one of the largest elective orthopaedic centres in the UK.
The study has been approved by Newcastle and North
Tyneside Research Ethics Committee (07/H0901/62) and
all participants provide informed http://www.controlled-
trials.com/ISRCTN25633145). Johnson & Johnson (UK)
has provided partial funding for this trial.Study duration
Recruitment into the trial began in December 2008, all
participants are now recruited and the 12-month follow-
up stage will be completed in early 2014.
Study participants
Participants deemed suitable for a total hip or total knee
replacement. Patients must satisfy general requirements
for a THR or TKR.
Inclusion criteria
There were no restrictions based on age, sex, previous
infections and all patient requiring a total hip or total
knee replacement at 1 of the 2 sites were included. All
patients were screened for MRSA and had to have a
negative swab prior to surgery.
Exclusion criteria
Require revision knee or hip replacement surgery.
Unicondylar or patellofemoral knee replacement.
Are unlikely to be able to perform required clinical
assessment task.
Participant recruitment
Patients were identified by participating surgeons and
approached in outpatients and at pre-assessment clinics
by research associates using good clinical practice princi-
ples. Patients were provided with a patient information
leaflet and a formal Invitation letter. Eligible patients
then had a minimum period of a week to consider entry
into the trial. Patients were recruited or given further in-
formation about the study at their pre-assessment visit.
A further opportunity to recruit patients is available on
admission for surgery.
All patients will be given sufficient time to accept or
decline involvement. It will be made clear verbally and
in written form, that they will be free to withdraw from
the study at any time without affecting their routine
perioperative care.
Participant allocation
Treatment group allocation is based upon an opaque en-
velope randomised design utilising the date surgery is
performed. This allocation is based on random monthly
hospital assignment into one of the two groups, each
centre providing one treatment for the whole calendar
month. Envelopes were only opened at the start of a
month, so allocation was not known at the time of list-
ing. Each month the hospitals would be randomised to
either control or intervention. A more optimal conven-
tional randomisation methodology, that is randomly al-
locating individual study participants to one of the two
treatment groups at recruitment, is not possible for this
study. It was decided by the study development team
Table 1 Health protection agency definition of superficial
surgical site infection
Superficial incisional infection
SSI that occurs within 30 days of surgery, involves only the skin or
subcutaneous tissue of the incision & meets at least one of the
following criteria:
1. Purulent drainage from superficial incision
2. Culture of organisms and pus cells present:
fluid/tissue from superficial incision wound swab from superficial
incision
3. At least 2 symptoms of inflammation:
Pain, tenderness, localised swelling, redness, heat and either:
1) Incision deliberately opened to manage infection
or
2) Clinicians diagnosis of superficial SSI
Note: Stitch abscesses (minimal inflammation/discharge at suture point) do
not classify as SSI.
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do this in the selected setting. Multiple sutures with a
variety of surgeon specific needle types would have been
used, so a considerable number of blinded sutures would
be needed, with the majority discarded. Equally we
would have to store large numbers of each suture in the
theatre if randomised individually. Lack of specific local
support for randomisation and concerns about the im-
pact on the credibility and fidelity of the study interven-
tions were identified as problematic issues if individual
participant randomisation were adopted. Within this
study setting the surgeon was not blinded to the sutures.
The study participants, research associates involved in
recruitment and assessment, and clinical staff involved
in the care of study participants were all blind to treat-
ment allocation throughout the study. The statistician is
also blinded.
Interventions
Hip and knee replacement participants
Before the operation, all patients followed the same pa-
tient pathway from out patient appointment to operation
date. The surgeon will be aware of the suture, which will
be used to close all layers of the wound, including the
subcutaneous skin in a subcuticular technique if deemed
appropriate by the operating surgeon. If a subcuticular
skin closure technique is not deemed appropriate then
metal clips will be used for the skin layer. Prophylactic
parenteral antibiotics prophylaxis at the start of trial was
Gentamicin (4.5 mg/kg) and this was changed to Genta-
micin (3 mg/kg) and Teicoplanin (400 mg) in February
2009 [15] in line with our trust prophylaxis for primary
joint replacement. On the initiation of the study the lat-
est systematic review stated there was insufficient evi-
dence to suggest that there was a significant difference
in the efficacy of cephalosporin’s compared with that of
teicoplanin or penicillin-derivatives, or that a particular
generation of cephalosporin’s was more effective than
another [16]. Antibiotics were given as a single dose,
within 30 minutes of induction.
Standard care group
This study is pragmatic in design and we did not stipu-
late method of analgesia, anaesthesia, and post-operative
care, however there is a well-developed enhanced recov-
ery programme which all surgeons follow. The surgical
approach, implants used and method of closure is left
entirely to individual surgeon preference. Standard su-
tures will be used.
Intervention group
The intervention group will receive exactly the same
regimen as the standard of care group, except they re-
ceived a triclosan coated suture used for wound closure.The suture contains a triclosan coating on the surface of
the suture, with a potential local antibiotic action. The
suture is a commercial product in common use, from
the same company to maintain consistency across con-
trol and intervention arm [4].
Risks
No additional risks for study patients were expected, since
all surgical procedures carried out within NASS represent
clinically established standard methods of treatment in
hip and knee replacement.
Primary outcome measure
The primary outcome is superficial SSI infection based
upon Health Protection Agency (HPA) published defini-
tions, which originate from the Centers for Disease Con-
trol and Prevention (CDC) 1992 published definition.
The HPA criteria are the nationally agreed definition
used within the UK, and routinely collected by the ma-
jority of UK Trusts [17]. Superficial incisional infection
is defined by the HPA, as a surgical site infection that
occurs within 30 days of surgery and involves only the
skin or subcutaneous tissue of the incision, and meets at
least one of the criteria in Table 1. To ensure accurate
collection the 30-day HPA patient self reported ques-
tionnaire was recorded in all patients collected by tele-
phone, by a blinded research nurse.
Secondary outcome measures
Deep incisional infection is defined as a surgical site in-
fection involving the deep tissues (i.e. fascial and muscle
layers) that occurs within a year, the infection appears to
be related to the surgical procedure, and meets at least
one of the criteria in Table 2. These criteria are those
nationally defined and validated.
Table 2 Health protection agency definition of deep
surgical site infection
Deep incisional infection
SSI involving the deep tissues (i.e. fascial & muscle layers), within 30 days
of surgery (or 1 year if an implant is in place) and the infection appears
to be related to the surgical procedure & meets at least one of the
following criteria:
1. Purulent drainage from deep incision (not organ space)
2. Organisms from culture and pus cells present in:
Fluid/tissue from deep incision or wound swab from deep incision
3. Deep incision dehisces or deliberately opened and patient has at
least 1 symptom of:
Fever or localised pain/tenderness
4. Abscess or other evidence of infection in deep incision:
Re-operation/histopathology/radiology
5. Clinicians diagnosis of deep incisional SSI
Note: An infection involving both superficial and deep incisional.
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This is calculated from participant’s admission and dis-
charge dates and is the number of nights in hospital.
30 and 90-day mortality
Mortality data were obtained from the Office of National
Statistics (ONS). In England, deaths must be registered
within 5 days. Burials and cremations cannot be con-
ducted without this registration documentation. These
deaths are recorded by the ONS and are added to the
patient’s health service record.
Medical and surgical complications
This data is recorded from hospital records during the
in-patient stay, and utilising Hospital Episode Statistics
data.
Pre operative patient factors
A number of possible potential prognostic factors are being
recorded, including socio-demographic factors and medical
co-morbidities. Due to the importance of these factors for
SSI multi-variant logistic regression analysis, adjusting for
pre operative factors will be performed.
Specific postoperative complications
An additional number of specific complications are be-
ing recorded such as Deep Vein Thrombosis (DVT) at
60 days, Pulmonary Embolism (PE) at 60 days, stroke at
30 days, Transient Ischemic Attack (TIA) at 30 days, GI
Bleed at 30 days (GIB), Urinary Retention at 30 days
(UR), Urinary tract infection (UTI) at 30 days, Myocar-
dial Infarction (MI) at 30 days, Pneumonia at 30 days
(RTI), and readmission rate. The blinded research nurse
will identify these complications for each patient in thetrial and HES data will be used as a secondary recording
method.
Sample size calculation
The primary outcome for this trial is SSI based on the
HPA defined criteria at 30 days post-operation. Two
thousand four hundred patients listed for primary hip or
total knee replacement are being recruited into the
study, and quasi randomised to the intervention arm or
the standard care arm. At the initiation of the study the
trusts 12 month audited rate of superficial SSI was
2.25% for hip and total knee replacement, which is
within that documented in the literature. This sample
size will provide 80% power to detect a reduction of SSI
infection from 2.25% to 1%, at the 5% level. This differ-
ence represents a significant reduction, which would
have an important clinical impact.
Statistical analysis
A CONSORT diagram [18] will summarise participant flow
through the study, documenting eligibility and recruitment,
receipt of intervention or standard care as allocated, and
collection of data [19]. Standard statistical summaries (e.g.
medians and ranges or means and variances, dependent on
the distribution of the outcome) and graphical plots show-
ing correlations will be presented for the primary outcome
measure and all secondary outcome measures. Baseline
data will be summarised to check comparability between
treatment arms, and to highlight any characteristic differ-
ences between those individuals in the study, those ineli-
gible, and those eligible but withholding consent. Although
missing data is not expected to be a major issue for this
study, the nature and pattern of the missingness will be
carefully considered — including in particular whether data
can be treated as missing completely at random (MCAR). If
judged appropriate, missing data will be imputed, and
resulting imputed datasets will be analysed and reported,
together with appropriate sensitivity analyses. Formal
analysis, for example using logistic regression with ‘missing-
ness’ as a response, may also be appropriate and aid
interpretation.
The primary outcome will be compared between
treatment groups using multi-variant logistic regression
analysis, adjusting for participant age, gender and co-
morbidity; regression coefficients will be considered to
be significant if p-values are less than 0.05 (5% signifi-
cance level). Estimates of treatment effects will be
presented with 95% confidence intervals. Although gen-
erally we have no reason to expect that the clustering ef-
fects will be important for this study, in reality the data
will be hierarchical in nature, with patients naturally
clustered into groups. Therefore we propose to account
for this by generalizing the conventional linear (fixed-ef-
fects) logistic regression approach to a more general
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in the model to account for heterogeneity. This analysis
will be presented in addition to the conventional fixed
effects model. All analyses will be conducted on an
intention-to-treat (ITT) basis, and reported as such;
additional per-protocol analyses will be undertaken and
reported if these prove to be informative.
Any subsequent amendments to this initial SAP will be
clearly stated and justified. Interim analyses will be per-
formed only where directed by the data monitoring com-
mittee (DMC). The routine statistical analysis will mainly
be carried out using R (http://www.r-project.org/) and S-
PLUS (http://www.insightful.com/).
Discussion
Surgical site infection in this population of patients is as-
sociated with increased mortality, morbidity, and pain,
which are well documented in the international litera-
ture [20]. For patients undergoing an elective procedure,
reduction of postoperative complications should be a
targeted objective for all doctors [21].
A targeted intervention ideally needs to be easily
adopted, low-intensity, independent of local hospital pol-
icy, and surgeon factors [22]. One of the great advantages
of this trial is the ease with which the intervention could
be applied pragmatically into any NHS hospital. The num-
ber of patients who develop SSI will continue to increase
as the number of these procedures increases, and there-
fore it is important that interventions optimise outcomes
after surgery are evaluated. Pragmatic RCTs represent the
highest level of evidence to assess the clinical effectiveness
of a new intervention. However, there are very few well-
designed and sufficiently powered RCTs of orthopaedic in-
terventions, in particular assessing SSI. Many orthopaedic
trials fail to be delivered due to lack of scientific rigor in
study design and execution. NASS is a pragmatic trial with
an appropriate sample size calculation, double blind, with
clearly defined inclusion and exclusion criteria, and infor-
mation on statistical analysis considered appropriately.
The trial has been specifically designed to demonstrate a
clinically important difference for patients, surgeons and
within the wider setting of the NHS.
The primary aim of the NASS trial is to determine if
the addition of a triclosan coated suture to the standard
regime within an NHS trust setting can significantly re-
duce SSI at 30 days after hip and knee replacement. The
results from this trial will inform evidence-based recom-
mendations for patients undergoing these common pro-
cedures in the UK and around the world. If a triclosan
coated suture is found to be an effective intervention, its
implementation into clinical practice could reduce SSI
in a broad range of surgical specialities, and therefore
improve long-term outcomes for patients undergoing a
broad range of surgical procedures.Abbreviations
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